Linagliptin noninferior for CV risk in early type 2 diabetes
(HealthDay)—Linagliptin is noninferior to glimepiride for adults with relatively early type 2 diabetes and elevated cardiovascular risk, according to a study published online Sept. 19 in the Journal of the American Medical ...
Sep 19, 2019
0
3